

Lisa H Butterfield

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4042750/lisa-h-butterfield-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172
papers

9,719
citations

55
h-index

94
g-index

199
ext. papers

11,618
ext. citations

8.9
avg, IF

6.15
L-index

#	Paper	IF	Citations
172	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020 , 577, 549-555	50.4	654
171	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1493-1501	21.7	544
170	Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3336-6	2.2	441
169	Immunotherapy of cancer in 2012. <i>Ca-A Cancer Journal for Clinicians</i> , 2012 , 62, 309-35	220.7	301
168	Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 1744-53	27.4	259
167	Current developments in cancer vaccines and cellular immunotherapy. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2415-32	2.2	254
166	Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. <i>PLoS ONE</i> , 2014 , 9, e87705	3.7	220
165	Baseline circulating IL-17 predicts toxicity while TGF- β and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma 2015 , 3, 39		200
164	Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2017 , 5, 480-492	12.5	196
163	Next generation of immunotherapy for melanoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3445-55	2.2	185
162	A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. <i>Clinical Cancer Research</i> , 2006 , 12, 2817-25	12.9	183
161	Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. <i>Clinical Cancer Research</i> , 2003 , 9, 998-1008	12.9	177
160	Cancer vaccines. <i>BMJ, The</i> , 2015 , 350, h988	5.9	156
159	Novel technologies and emerging biomarkers for personalized cancer immunotherapy 2016 , 4, 3		146
158	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy 2017 , 5, 44		139
157	Dendritic Cell-Based Cancer Vaccines. <i>Journal of Immunology</i> , 2018 , 200, 443-449	5.3	138
156	Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2058-6	2.2	135

155	Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation 2016 , 4, 76		122
154	Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. <i>Onc Immunology</i> , 2012 , 1, 48-55	7.2	121
153	Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. <i>Clinical Cancer Research</i> , 2009 , 15, 1443-51	12.9	120
152	From cytoprotection to tumor suppression: the multifactorial role of peroxiredoxins. <i>Antioxidants and Redox Signaling</i> , 1999 , 1, 385-402	8.4	119
151	T cell assays and MIATA: the essential minimum for maximum impact. <i>Immunity</i> , 2012 , 37, 1-2	32.3	117
150	T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. <i>Journal of Immunology</i> , 2001 , 166, 5300-8	5.3	117
149	T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. <i>Clinical Cancer Research</i> , 2003 , 9, 5902-8	12.9	116
148	Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. <i>Human Gene Therapy</i> , 2000 , 11, 53-65	4.8	106
147	Consensus nomenclature for CD8 T cell phenotypes in cancer. <i>Onc Immunology</i> , 2015 , 4, e998538	7.2	101
146	Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. <i>Journal of Immunotherapy</i> , 2004 , 27, 354-67	5	100
145	Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. <i>Journal of Immunotherapy</i> , 2008 , 31, 294-309	5	97
144	Phase I dendritic cell p53 peptide vaccine for head and neck cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 2433-44	12.9	95
143	Cloning and sequence analysis of candidate human natural killer-enhancing factor genes. <i>Immunogenetics</i> , 1994 , 40, 129-34	3.2	95
142	Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. <i>Journal of Immunology</i> , 2004 , 173, 2462-9	5.3	94
141	Determinant spreading and tumor responses after peptide-based cancer immunotherapy. <i>Trends in Immunology</i> , 2003 , 24, 58-61	14.4	92
140	Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. <i>Journal of Translational Medicine</i> , 2007 , 5, 67	8.5	89
139	Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. <i>Clinical Cancer Research</i> , 2011 , 17, 3064-76	12.9	87
138	Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. <i>Cytotherapy</i> , 2017 , 19, 1225-1232	4.8	86

137	Zinc in innate and adaptive tumor immunity. <i>Journal of Translational Medicine</i> , 2010 , 8, 118	8.5	85
136	Dendritic cells in cancer immunotherapy clinical trials: are we making progress?. <i>Frontiers in Immunology</i> , 2013 , 4, 454	8.4	81
135	Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative	2.2	80
134	In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. <i>Human Gene Therapy</i> , 1997 , 8, 2173-82	4.8	80
133	Immunotherapeutic strategies for hepatocellular carcinoma. <i>Gastroenterology</i> , 2004 , 127, S232-41	13.3	80
132	ATIM-11. PILOT STUDY OF TUMOR LYSATE VACCINE AND IMIQUIMOD IN ADULTS WITH WHO GRADE II GLIOMAS. <i>Neuro-Oncology</i> , 2017 , 19, vi28-vi28	1	78
131	Tumor-derived alpha-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells 2014 , 2,		78
130	Pilot trial of a type I - polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer 2015 , 3,		78
129	A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). <i>Clinical Cancer Research</i> , 2013 , 19, 4228-38	12.9	77
128	Antioxidant function of recombinant human natural killer enhancing factor. <i>Biochemical and Biophysical Research Communications</i> , 1995 , 208, 964-9	3.4	76
127	Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. <i>Clinical Cancer Research</i> , 2015 , 21, 286-94	12.9	75
126	Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations 2016 , 4, 77		68
125	Cancer immunotherapy using gene-modified dendritic cells. <i>Current Gene Therapy</i> , 2002 , 2, 57-78	4.3	64
124	Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. <i>Journal of Immunology</i> , 2006 , 177, 712-21	5.3	60
123	Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. <i>Journal of Immunotherapy</i> , 2000 , 23, 59-66	5	57
122	Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon- γ TLR-9 agonist and GM-CSF with peptide vaccination. <i>Journal of Immunotherapy</i> , 2012 , 35, 702-10	5	56
121	Web-based collaborative care intervention to manage cancer-related symptoms in the palliative care setting. <i>Cancer</i> , 2016 , 122, 1270-82	6.4	55
120	Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. <i>Blood</i> , 2010 , 116, 575-83	2.2	55

119	Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. <i>Journal of Immunotherapy</i> , 2004 , 27, 191-200	5	55
118	Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 1157-68	1	53
117	Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 1931-43	7.4	51
116	Tumor-derived Fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells. <i>Journal of Immunology</i> , 2014 , 193, 5723-32	5.3	45
115	AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients. <i>Journal of Immunotherapy</i> , 2007 , 30, 425-37	5	45
114	Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein. <i>Molecular Immunology</i> , 2000 , 37, 943-50	4.3	45
113	Development of a potency assay for human dendritic cells: IL-12p70 production. <i>Journal of Immunotherapy</i> , 2008 , 31, 89-100	5	42
112	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop 2019 , 7, 131		41
111	Immune oncology, immune responsiveness and the theory of everything 2018 , 6, 50		40
110	Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. <i>Cancer Prevention Research</i> , 2018 , 11, 429-438	3.2	38
109	A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. <i>European Urology</i> , 2015 , 68, 365-71	10.2	37
108	Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. <i>Journal of Neuro-Oncology</i> , 2016 , 130, 517-527	4.8	36
107	Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. <i>Journal of Translational Medicine</i> , 2014 , 12, 86	8.5	36
106	Multiplex serum biomarker assessments: technical and biostatistical issues. <i>Journal of Translational Medicine</i> , 2011 , 9, 173	8.5	35
105	Cancer-related symptom clusters, eosinophils, and survival in hepatobiliary cancer: an exploratory study. <i>Journal of Pain and Symptom Management</i> , 2010 , 39, 859-71	4.8	35
104	Melanoma cancer vaccines and anti-tumor T cell responses. <i>Journal of Cellular Biochemistry</i> , 2007 , 102, 301-10	4.7	35
103	Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). <i>International Journal of Cancer</i> , 2012 , 131, 874-84	7.5	34
102	Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. <i>Molecular Therapy</i> , 2011 , 19, 805-14	11.7	32

101	Prospective Clinical Testing of Regulatory Dendritic Cells in Organ Transplantation. <i>Frontiers in Immunology</i> , 2016 , 7, 15	8.4	32
100	Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients. <i>Clinical and Developmental Immunology</i> , 2011 , 2011, 249281		31
99	Melanoma-associated leukoderma - immunology in black and white?. <i>Pigment Cell and Melanoma Research</i> , 2013 , 26, 796-804	4.5	30
98	Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. <i>Hepatology</i> , 2014 , 59, 1448-58	11.2	30
97	Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells. <i>Cancer Gene Therapy</i> , 1999 , 6, 523-36	5.4	30
96	Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 121-33	7.4	29
95	Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro. <i>Journal of Immunology</i> , 2009 , 183, 7250-8	5.3	28
94	Cancer immunotherapy trials: leading a paradigm shift in drug development 2016 , 4, 42		28
93	Recent advances in immunotherapy for hepatocellular cancer. <i>Swiss Medical Weekly</i> , 2007 , 137, 83-90	3.1	28
92	Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10. <i>Oncolmunology</i> , 2012 , 1, 448-457	7.2	25
91	Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. <i>Journal of Translational Medicine</i> , 2007 , 5, 68	8.5	25
90	Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. <i>Cancer Gene Therapy</i> , 2005 , 12, 516-27	5.4	25
89	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). <i>Clinical Cancer Research</i> , 2017 , 23, 5034-5043	12.9	24
88	Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?. <i>Immunologic Research</i> , 2011 , 50, 235-47	4.3	24
87	SITC/ISBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. <i>Journal of Translational Medicine</i> , 2011 , 9, 155	8.5	24
86	Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro. <i>Cancer Research</i> , 2003 , 63, 5607-14	10.1	24
85	CD56 CD16 Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon- γ <i>Frontiers in Immunology</i> , 2019 , 10, 14	8.4	22
84	Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab 2016 , 4, 38		22

83	Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. <i>Onc Immunology</i> , 2012 , 1, 287-357	7.2	21
82	Cloning and analysis of MART-1/Melan-A human melanoma antigen promoter regions. <i>Gene</i> , 1997 , 191, 129-34	3.8	21
81	Genetic immunotherapy for cancer. <i>Oncologist</i> , 2000 , 5, 87-98	5.7	21
80	Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. <i>Journal of Clinical Investigation</i> , 2020 , 130, 6325-6337	15.9	21
79	Lessons learned from cancer vaccine trials and target antigen choice. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 805-12	7.4	20
78	High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. <i>Cellular Immunology</i> , 2018 , 323, 9-18	4.4	19
77	Randomized controlled trial of a collaborative care intervention to manage cancer-related symptoms: lessons learned. <i>Clinical Trials</i> , 2011 , 8, 298-310	2.2	19
76	Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. <i>Journal of Immunology</i> , 2004 , 172, 4762-9	5.3	18
75	Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells. <i>Immunology</i> , 2004 , 113, 472-81	7.8	18
74	Immunotherapy of hepatocellular carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2002 , 2, 123-33	5.4	18
73	Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. <i>Journal of Translational Medicine</i> , 2018 , 16, 184	8.5	18
72	Immunotherapy biomarkers 2016: overcoming the barriers 2017 , 5, 29		17
71	Prospective Analyses of Cytokine Mediation of Sleep and Survival in the Context of Advanced Cancer. <i>Psychosomatic Medicine</i> , 2018 , 80, 483-491	3.7	16
70	Systematic evaluation of immune regulation and modulation 2017 , 5, 21		15
69	Tumor-Derived Fetoprotein Suppresses Fatty Acid Metabolism and Oxidative Phosphorylation in Dendritic Cells. <i>Cancer Immunology Research</i> , 2019 , 7, 1001-1012	12.5	15
68	Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer 2016 , 4, 24		15
67	Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients. <i>Journal of Immunological Methods</i> , 2012 , 376, 108-12	2.5	15
66	Alpha-fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer. <i>Expert Opinion on Biological Therapy</i> , 2008 , 8, 325-36	5.4	15

65	Activation of antigen-presenting cells by DNA delivery vectors. <i>Expert Opinion on Biological Therapy</i> , 2005 , 5, 1019-28	5.4	15
64	Multiple antigen-engineered DC vaccines with or without IFN α to promote antitumor immunity in melanoma 2019 , 7, 113		14
63	Dendritic cell control of immune responses. <i>Frontiers in Immunology</i> , 2015 , 6, 42	8.4	14
62	Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas. <i>JCI Insight</i> , 2018 , 3,	9.9	14
61	Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	14
60	Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sjögren syndrome. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 423-434	7.4	14
59	Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. <i>Melanoma Research</i> , 2018 , 28, 211-221	3.3	13
58	Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma 2015 , 3, 32		13
57	Molecular mimicry of MAGE-A6 and HF-2 epitopes in the induction of antitumor CD8 T-cell responses. <i>Onc Immunology</i> , 2014 , 3, e954501	7.2	13
56	Tumor-Derived Fetoprotein Directly Drives Human Natural Killer-Cell Activation and Subsequent Cell Death. <i>Cancer Immunology Research</i> , 2017 , 5, 493-502	12.5	12
55	Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines. <i>Cancer Gene Therapy</i> , 2002 , 9, 875-83	5.4	12
54	New approaches to the development of adenoviral dendritic cell vaccines in melanoma. <i>Current Opinion in Investigational Drugs</i> , 2010 , 11, 1399-408		12
53	First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells. <i>Journal of Translational Medicine</i> , 2019 , 17, 271	8.5	11
52	The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. <i>Seminars in Cancer Biology</i> , 2018 , 52, 12-15	12.7	10
51	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy) 2018 , 6, 69		10
50	A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 783-8	7.4	9
49	Melanoma vaccines: clinical status and immune endpoints. <i>Melanoma Research</i> , 2019 , 29, 109-118	3.3	9
48	Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon- β but Not Observation in Intermediate Risk Melanoma Patients. <i>PLoS ONE</i> , 2015 , 10, e0132745	3.7	8

47	Peptide vaccine therapy for childhood gliomas. <i>Neurosurgery</i> , 2013 , 60 Suppl 1, 113-9	3.2	8
46	Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo. <i>International Journal of Oncology</i> , 2011 , 39, 245-53	4.4	8
45	Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab. <i>Journal of Translational Medicine</i> , 2017 , 15, 39	8.5	7
44	Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017 , 7, 112-122	6.4	7
43	Immunologic monitoring of cancer vaccine trials using the ELISPOT assay. <i>Methods in Molecular Biology</i> , 2014 , 1102, 71-82	1.4	7
42	Interleukin 32 expression in human melanoma. <i>Journal of Translational Medicine</i> , 2019 , 17, 113	8.5	6
41	Rational design of peptide-based tumor vaccines. <i>Pharmaceutical Research</i> , 2002 , 19, 926-32	4.5	6
40	Dysregulated NF- κ B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. <i>Cancer Immunology Research</i> , 2020 , 8, 1554-1567	12.5	6
39	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee 2020 , 8,		6
38	Ependymomas: development of immunotherapeutic strategies. <i>Expert Review of Neurotherapeutics</i> , 2013 , 13, 1089-98	4.3	5
37	Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. <i>Contemporary Clinical Trials</i> , 2004 , 25, 400-7		5
36	Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy 2020 , 8,		5
35	NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. <i>Cancer</i> , 2018 , 124, 4332-4341	6.4	5
34	Adverse childhood experiences (ACEs), cell-mediated immunity, and survival in the context of cancer. <i>Brain, Behavior, and Immunity</i> , 2020 , 88, 566-572	16.6	4
33	Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016 2017 , 5, 55		4
32	Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma 2013 , 1, 19		4
31	Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. <i>Cellular Immunology</i> , 2019 , 335, 59-67	4.4	4
30	Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR 2021 , 9,		4

29	Preamble to the 2015 SITC immunotherapy biomarkers taskforce 2015 , 3, 8		3
28	Accelerating the development of innovative cellular therapy products for the treatment of cancer. <i>Cytotherapy</i> , 2020 , 22, 239-246	4.8	3
27	Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines23-43		3
26	Web-based stepped collaborative care intervention in the context of advanced cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9522-9522	2.2	3
25	Dose-response evaluation of brocolli sprout extract sulforaphane (BSE-SFN) in melanoma patients (Pts) with atypical/dysplastic nevi (A/DN).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21022-e21022	2.2	3
24	Neoadjuvant Pembrolizumab and High-Dose IFN γ in Resectable Regionally Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021 , 27, 4195-4204	12.9	3
23	The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018 2019 , 7, 221		2
22	185 Peptide Vaccine Therapy for Childhood GliomasInterim Results of a Pilot Study. <i>Neurosurgery</i> , 2012 , 71, E572	3.2	2
21	Neoadjuvant ipilimumab in locally/regionally advanced melanoma: Clinical outcome and biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 76-76	2.2	2
20	Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma 2021 , 9,		2
19	Hallmarks of Resistance to Immune-Checkpoint Inhibitors.. <i>Cancer Immunology Research</i> , 2022 , 10, 372-383	3.5	2
18	Measurements of natural killer (NK) cells. <i>Critical Reviews in Oncogenesis</i> , 2014 , 19, 47-55	1.3	1
17	Cancer and the Immune System573-591		1
16	Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 1649-1649	2.2	1
15	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy). <i>Journal of Translational Medicine</i> , 2021 , 19, 13	8.5	1
14	Isolation, culture and propagation of natural killer cells 2010 , 125-135		0
13	Cytokine Assays 2016 , 1-11		
12	Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule 2016 , 4, 37		

- 11 DNA and Dendritic Cell-Based Genetic Immunization Against Cancer **2002**, 179-198
- 10 Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation-positive melanoma with metastases to the brain (BRV116521).. *Journal of Clinical Oncology*, **2014**, 32, TPS9112-TPS9112 2.2
- 9 Regulatory T Cell Response to Factor VIII in Mothers of Children with Hemophilia Inhibitors. *Blood*, **2015**, 126, 3512-3512 2.2
- 8 Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab.. *Journal of Clinical Oncology*, **2016**, 34, e21059-e21059 2.2
- 7 Dendritic Cell Vaccines for Immunotherapy of Cancer: Challenges in Clinical Trials **2009**, 159-172
- 6 Comparison of SearchLight and Luminex multiplex assays: A case study of 27 cytokines in 156 melanoma blood serum samples.. *Journal of Clinical Oncology*, **2012**, 30, 79-79 2.2
- 5 Approaches to Immunologic Monitoring of Clinical Trials **2013**, 663-694
- 4 Insights into the Process of Translating Emerging Immunologic Paradigms to Clinical Trial in Patients with Cancer **2014**, 205-219
- 3 The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020. *Journal of Translational Medicine*, **2021**, 19, 144 8.5
- 2 Novel dendritic cell vaccine strategies **2022**, 109-135
- 1 The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.. *Journal of Translational Medicine*, **2022**, 20, 179 8.5